BiTEs: Bispecific antibody constructs with unique anti-tumor activity

Drug Discovery Today

Volumn 10, Issue 18, 2005, Pages 1237-1244

  Wolf, Evelyn ^a   Hofmeister, Robert ^a   Kufer, Peter ^a   Schlereth, Bernd ^a   Baeuerle, Patrick A ^a  

^a MICROMET AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC T CELL ENGAGER MOLECULE; MONOCLONAL ANTIBODY CD3; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG POTENCY; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; NONHUMAN; REVIEW; T LYMPHOCYTE; TARGET CELL; TUMOR CELL;

ANIMALS; ANTIBODIES, BISPECIFIC; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES;

EID: 26244466523     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03554-3     Document Type: Review

References (54)

1. P. Carter Improving the efficacy of antibody-based cancer therapies Nat. Rev. Cancer 1 2001 118 129
2. P. Kufer A revival of bispecific antibodies Trends Biotechnol. 22 2004 238 244
3. B. Seliger Antigen-processing machinery breakdown and tumor growth Immunol. Today 21 2000 455 464
4. T. Hayashi, D.L. Faustman Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice Cancer Res. 62 2002 24 27
5. G. Gobbi Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions Int. J. Oncol. 25 2004 1625 1629
6. A.K. Johnsen Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis J. Immunol. 163 1999 4224 4231
7. U. Ritz Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma Int. J. Oncol. 19 2001 1211 1220
8. J. Bubenik MHC class I down-regulation: tumour escape from immune surveillance? (review) Int. J. Oncol. 25 2004 487 491
9. D.J. Hicklin HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story Mol. Med. Today 5 1999 178 186
10. T. Kageshita Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression Am. J. Pathol. 154 1999 745 754
11. R.C. Rees, S. Mian Selective MHC expression in tumours modulates adaptive and innate antitumour responses Cancer Immunol. Immunother. 48 1999 374 381
12. C.M. Cabrera Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors Tissue Antigens 61 2003 211 219
13. J.C. Becker Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity J. Immunol. 147 1991 4398 4401
14. K.N. Balaji Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation J. Exp. Med. 196 2002 493 503
15. J.P. Medema Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors Proc. Natl. Acad. Sci. U. S. A. 98 2001 11515 11520
16. S.I. Abrams Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response Front. Biosci. 10 2005 809 821
17. Y. Iwai PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells Int. Immunol. 17 2005 133 144
18. A. Fontana Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice J. Immunol. 143 1989 3230 3234
19. L. Gorelik, R.A. Flavell Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells Nat. Med. 7 2001 1118 1122
20. E. Venetsanakos High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours Br. J. Cancer 75 1997 1826 1830
21. T.F. Gajewski Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1 Curr. Opin. Investig. Drugs 5 2004 1279 1283
22. C. Uyttenhove Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat. Med. 9 2003 1269 1274
23. A. Garcia-Lora MHC class I antigens, immune surveillance, and tumor immune escape J. Cell. Physiol. 195 2003 346 355
24. L.A. Emens, E.M. Jaffee Cancer vaccines: an old idea comes of age Cancer Biol. Ther. 2 4, Suppl. 1 2003 S161 S168
25. A.P. Makrigiannis, S.K. Anderson Regulation of natural killer cell function Cancer Biol. Ther. 2 2003 610 616
26. J. Wu, L.L. Lanier Natural killer cells and cancer Adv. Cancer Res. 90 2003 127 156
27. S. Withoff Bi-specific antibody therapy for the treatment of cancer Curr. Opin. Mol. Ther. 3 2001 53 62
28. P.A. Baeuerle Bispecific antibodies for polyclonal T-cell engagement Curr. Opin. Mol. Ther. 5 2003 413 419
29. B. Gatto Monoclonal antibodies in cancer therapy Curr. Med. Chem. Anti-Canc. Agents 4 2004 411 414
30. J.S. Huston Protein engineering of single-chain Fv analogs and fusion proteins Methods Enzymol. 203 1991 46 88
31. W.D. Mallender, E.W. Voss Jr. Construction, expression, and activity of a bivalent bispecific single-chain antibody J. Biol. Chem. 269 1994 199 206
32. Offner S. et al., Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs. Mol. Immunol. (in press)
33. A. Loffler A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes Blood 95 2000 2098 2103
34. A. Loffler Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct Leukemia 17 2003 900 909
35. T. Dreier Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody Int. J. Cancer 100 2002 690 697
36. B. Schlereth Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct Cancer Res. 65 2005 2882 2889
37. P. Hoffmann Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct Int. J. Cancer 115 2005 98 104
38. M. Mack A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity Proc. Natl. Acad. Sci. U. S. A. 92 1995 7021 7025
39. M. Mack Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity J. Immunol. 158 1997 3965 3970
40. L. Ren-Heidenreich Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model Cancer 100 2004 1095 1103
41. J. De Jonge Production and characterization of bispecific single-chain antibody fragments Mol. Immunol. 32 1995 1405 1412
42. J. De Jonge In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 × anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model J. Immunol. 161 1998 1454 1461
43. M. Gruber Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J. Immunol. 152 1994 5368 5374
44. K.A. Browne Cytosolic delivery of granzyme B by bacterial toxins: evidence that endosomal disruption, in addition to transmembrane pore formation, is an important function of perforin Mol. Cell. Biol. 19 1999 8604 8615
45. M. Gruen T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent Cancer Immunol. Immunother. 53 2004 625 632
46. T. Dreier T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct J. Immunol. 170 2003 4397 4402
47. P. Kufer Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer Cancer Immunol. Immunother. 45 1997 193 197
48. M.L. Dustin, A.S. Shaw Costimulation: building an immunological synapse Science 283 1999 649 650
49. J.C. Stinchcombe The immunological synapse of CTL contains a secretory domain and membrane bridges Immunity 15 2001 751 761
50. Schlereth B. et al, T-cell activation and B-cell depletion in chimpanzees treated with a bispecific CD19-/CD3-bispecific single-chain construct. Cancer Immunol. Immunother. (in press)
51. Brischwein et al, (2005) MT110: a novel bispecific single-chain antibody construct with high efficacy in erradicating established tumors. Mol. Immunol. (in press)
52. T.L. Whiteside Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors Int. J. Cancer 37 1986 803 811
53. S. Miescher Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors J. Immunol. 138 1987 4004 4011
54. S. Miescher Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes J. Immunol. 136 1986 1899 1907